[1]JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034
[1]JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034
[1]JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034
[1]JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034
[1]JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034
[1]Lee,HelenT.;Sliskovic,DragoR.;Picard,JosephA.;Roth,BruceD.;Wierenga,Wendell;Hicks,JamesL.;Bousley,RichardF.;Hamelehle,KatherineL.;Homan,Reynold;Speyer,Cecilia;Stanfield,RichardL.;Krause,BrianR.[JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034]
[1]Lee,HelenT.;Sliskovic,DragoR.;Picard,JosephA.;Roth,BruceD.;Wierenga,Wendell;Hicks,JamesL.;Bousley,RichardF.;Hamelehle,KatherineL.;Homan,Reynold;Speyer,Cecilia;Stanfield,RichardL.;Krause,BrianR.[JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034]
[1]Lee,HelenT.;Sliskovic,DragoR.;Picard,JosephA.;Roth,BruceD.;Wierenga,Wendell;Hicks,JamesL.;Bousley,RichardF.;Hamelehle,KatherineL.;Homan,Reynold;Speyer,Cecilia;Stanfield,RichardL.;Krause,BrianR.[JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034]
[1]Lee,HelenT.;Sliskovic,DragoR.;Picard,JosephA.;Roth,BruceD.;Wierenga,Wendell;Hicks,JamesL.;Bousley,RichardF.;Hamelehle,KatherineL.;Homan,Reynold;Speyer,Cecilia;Stanfield,RichardL.;Krause,BrianR.[JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034]
[1]Lee,HelenT.;Sliskovic,DragoR.;Picard,JosephA.;Roth,BruceD.;Wierenga,Wendell;Hicks,JamesL.;Bousley,RichardF.;Hamelehle,KatherineL.;Homan,Reynold;Speyer,Cecilia;Stanfield,RichardL.;Krause,BrianR.[JournalofMedicinalChemistry,1996,vol.39,#26,p.5031-5034]
Title: Coronary circulatory function in patients with the metabolic syndrome.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110901
Title: The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.
Journal: Journal of neuropathology and experimental neurology 20100801
Title: Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines.
Journal: Cancer biology & therapy 20100615
Title: Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20091101
Title: Synthesis and structure-activity relationships of N-(4-amino-2,6-diisopropylphenyl)-N'-(1,4-diarylpiperidine-4-yl)methylureas as anti-hyperlipidemic agents.
Journal: Bioorganic & medicinal chemistry 20090701
Title: Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
Journal: Bioorganic & medicinal chemistry letters 20090215
Title: Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
Journal: Journal of biochemical and molecular toxicology 20090101
Title: Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
Journal: Journal of medicinal chemistry 20080814
Title: In silico prediction of pregnane X receptor activators by machine learning approaches.
Journal: Molecular pharmacology 20070101
Title: Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Journal: Pathophysiology of haemostasis and thrombosis 20070101
Title: Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20061001
Title: [New agents against atherosclerosis tested. Alarming findings, ACAT inhibitors seem to have proatherogenic effects].
Journal: Lakartidningen 20061001
Title: Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound.
Journal: The American journal of cardiology 20060701
Title: The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Journal: Biochimica et biophysica acta 20051230
Title: Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Journal: Current drug targets. Cardiovascular & haematological disorders 20051201
Title: Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20041201
Title: Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Journal: Circulation 20041123
Title: Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Journal: DNA and cell biology 20040501
Title: Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Journal: Atherosclerosis 20031201
Title: Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Journal: The Journal of pharmacology and experimental therapeutics 20030901
Title: Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Journal: Cardiovascular drug reviews 20030101
Title: Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.
Journal: American heart journal 20021001
Title: Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Journal: European journal of pharmacology 20020906
Title: Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages.
Journal: Atherosclerosis 20020301
Title: Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Journal: Biochemical pharmacology 20020201
Title: New advances in lipid-modifying therapies for reducing cardiovascular risk.
Journal: Cardiology 20020101
Title: A role for smooth endoplasmic reticulum membrane cholesterol ester in determining the intracellular location and regulation of sterol-regulatory-element-binding protein-2.
Journal: The Biochemical journal 20010901
Title: Therapies on the horizon for cholesterol reduction.
Journal: Clinical cardiology 20010801
Title: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Journal: Atherosclerosis 20010701
Title: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Journal: Atherosclerosis 20010701
Title: Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Journal: Circulation 20010403
Title: Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20010201
